AnaptysBio, Inc. Common Stock ANAB
i
Market datapartial · fetched 2026-11-12T03:01:21.985Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T22:22:12.623317936Z
FundamentalsAlpha Vantage · unavailable
AnaptysBio, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 40.47 | 172.3% | 20.9% | |||
| 25Δ | 61.49 | 179.9% | 29.4% | 42.28 | 172.5% | 18.5% |
| 30Δ | 60.07 | 194.1% | 27.5% | 44.09 | 172.7% | 16.1% |
| 35Δ | 56.18 | 164.9% | 19.9% | 45.67 | 164.5% | 13.7% |
| 40Δ | 53.59 | 142.8% | 14.9% | 47.03 | 147.6% | 11.3% |
| 45Δ | 51.59 | 124.6% | 11.1% | 48.39 | 130.8% | 8.8% |
| 50Δ | 49.78 | 110.2% | 7.9% | 49.74 | 113.9% | 6.4% |
| 55Δ | 48.67 | 111.0% | 6.9% | 51.06 | 112.2% | 5.4% |
| 60Δ | 47.57 | 111.9% | 5.9% | 52.36 | 113.9% | 4.6% |
| 65Δ | 46.46 | 112.8% | 4.9% | 53.66 | 115.6% | 3.8% |
| 70Δ | 45.35 | 113.7% | 3.9% | 54.96 | 117.3% | 3.1% |
| 75Δ | 43.88 | 117.0% | 3.1% | 56.67 | 116.8% | 2.4% |
| 80Δ | 42.24 | 121.4% | 2.4% | 58.40 | 116.1% | 1.8% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 40.47
- IV
- 172.3%
- B/E move
- 20.9%
25Δ
- Pseudo strike
- 61.49
- IV
- 179.9%
- B/E move
- 29.4%
- Pseudo strike
- 42.28
- IV
- 172.5%
- B/E move
- 18.5%
30Δ
- Pseudo strike
- 60.07
- IV
- 194.1%
- B/E move
- 27.5%
- Pseudo strike
- 44.09
- IV
- 172.7%
- B/E move
- 16.1%
35Δ
- Pseudo strike
- 56.18
- IV
- 164.9%
- B/E move
- 19.9%
- Pseudo strike
- 45.67
- IV
- 164.5%
- B/E move
- 13.7%
40Δ
- Pseudo strike
- 53.59
- IV
- 142.8%
- B/E move
- 14.9%
- Pseudo strike
- 47.03
- IV
- 147.6%
- B/E move
- 11.3%
45Δ
- Pseudo strike
- 51.59
- IV
- 124.6%
- B/E move
- 11.1%
- Pseudo strike
- 48.39
- IV
- 130.8%
- B/E move
- 8.8%
50Δ
- Pseudo strike
- 49.78
- IV
- 110.2%
- B/E move
- 7.9%
- Pseudo strike
- 49.74
- IV
- 113.9%
- B/E move
- 6.4%
55Δ
- Pseudo strike
- 48.67
- IV
- 111.0%
- B/E move
- 6.9%
- Pseudo strike
- 51.06
- IV
- 112.2%
- B/E move
- 5.4%
60Δ
- Pseudo strike
- 47.57
- IV
- 111.9%
- B/E move
- 5.9%
- Pseudo strike
- 52.36
- IV
- 113.9%
- B/E move
- 4.6%
65Δ
- Pseudo strike
- 46.46
- IV
- 112.8%
- B/E move
- 4.9%
- Pseudo strike
- 53.66
- IV
- 115.6%
- B/E move
- 3.8%
70Δ
- Pseudo strike
- 45.35
- IV
- 113.7%
- B/E move
- 3.9%
- Pseudo strike
- 54.96
- IV
- 117.3%
- B/E move
- 3.1%
75Δ
- Pseudo strike
- 43.88
- IV
- 117.0%
- B/E move
- 3.1%
- Pseudo strike
- 56.67
- IV
- 116.8%
- B/E move
- 2.4%
80Δ
- Pseudo strike
- 42.24
- IV
- 121.4%
- B/E move
- 2.4%
- Pseudo strike
- 58.40
- IV
- 116.1%
- B/E move
- 1.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 79.49% | |
| 79.51% | |
| 86.46% | |
| 91.87% | |
| 89.92% | |
| 68.38% | |
| 71.28% | |
| 68.61% | |
| 68.19% | |
| 68.27% | |
| 67.09% | |
| 67.84% | |
| 67.86% | |
| 70.44% | |
| 67.55% | |
| 68.78% | |
| 73.61% | |
| 73.79% | |
| 76.79% | |
| 70.69% | |
| 84.03% | |
| 82.84% | |
| 88.16% | |
| 93.28% | |
| 70.21% | |
| 69.27% | |
| 72.15% | |
| 72.53% | |
| 71.26% | |
| 72.31% | |
| 74.65% | |
| 73.07% | |
| 75.36% | |
| 76.60% | |
| 77.13% | |
| 79.13% | |
| 80.91% | |
| 81.42% | |
| 103.37% | |
| 113.23% | |
| 82.58% | |
| 85.12% | |
| 85.11% | |
| 78.67% | |
| 83.70% | |
| 81.31% | |
| 79.91% | |
| 78.50% | |
| 75.89% | |
| 76.72% | |
| 83.87% |
Biotechnology
ANIX
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company is…
More →ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases. The company is headquartered in South…
More →ANRO
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company is headquartered in Los Altos,…
More →ANTX
Anthem, Inc., is a health benefits company in the United States. The company is headquartered in Indianapolis, Indiana.
More →ARCT
Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. The company is headquartered in San Diego, California.
More →ARDX
Description unavailable
More →